Human Immunodeficiency Virus – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of human immunodeficiency virus (HIV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of HIV for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s HIV forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HIV over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts seven HIV patient populations, as follows:
- Prep-eligible population
- Diagnosed incident cases
- Diagnosed prevalent cases
- Undiagnosed prevalent cases
- Drug-treated prevalent cases
- Non-drug-treated prevalent cases
- Total prevalent cases
Note: Coverage may vary by country.
